RI
SYRE icon

RTW Investments’s Spyre Therapeutics SYRE Stock Holding History

RTW Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377M Buy
4,251,996
+80,000
+2% +$5.84M 3.22% 8
2026
Q1 		$210M Hold
4,171,996
– – 2.09% 14
2025
Q4 		$137M Buy
4,171,996
+550,000
+15% +$14.4M 1.37% 23
2025
Q3 		$60.7M Hold
3,621,996
– – 0.75% 35
2025
Q2 		$54.2M Hold
3,621,996
– – 0.77% 34
2025
Q1 		$58.4M Hold
3,621,996
– – 0.89% 29
2024
Q4 		$84.3M Buy
3,621,996
+363,636
+11% +$10.7M 1.28% 26
2024
Q3 		$95.8M Hold
3,258,360
– – 1.39% 28
2024
Q2 		$76.6M Buy
3,258,360
+1,025,600
+46% +$34.6M 1.19% 28
2024
Q1 		$84.7M Hold
2,232,760
– – 1.25% 30
2023
Q4 		$48M Buy
+2,232,760
New +$30.8M 0.75% 34

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments's SYRE Position: Q2 2026 in Review

RTW Investments increased its Spyre Therapeutics (SYRE) stake by 1.9% in Q2 2026, buying an estimated $5.84M and bringing the position to 4,251,996 shares worth $377M. The position accounts for 3.22% of the portfolio, ranked #8.

RTW Investments first reported a position in SYRE in Q4 2023 and has held it in 11 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • RTW Investments held 4,251,996 shares of Spyre Therapeutics worth $377M as of Q2 2026.
  • RTW Investments bought 80,000 Spyre Therapeutics shares in Q2 2026, an estimated $5.84M.
  • Spyre Therapeutics made up 3.22% of RTW Investments's portfolio in Q2 2026, its #8 holding.
  • RTW Investments first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.